Neuroendocrine Tumors Treatment Market

Market Overview

The global neuroendocrine tumors treatment market size was valued at USD 3.24 Billion in 2023. It is estimated to reach USD 7.87 Billion by 2032, growing at a CAGR of 10.40% during the forecast period (2024–2032).

Treatment for neuroendocrine tumors involves various approaches, including surgical removal of localized tumors, medical therapies like somatostatin analogs and targeted drugs, peptide receptor radionuclide therapy (PRRT), liver-directed treatments, and radiation therapy. The specific treatment plan depends on the tumor's type, location, grade, and stage, as well as patient health. Additionally, ongoing clinical trials and research are continuously exploring new therapeutic options to improve outcomes, making personalized medicine an essential aspect of managing NETs.

The neuroendocrine tumor treatment market is expanding due to rising awareness and improved diagnostic capabilities, leading to more accurate and timely diagnoses. Additionally, advancements in treatment options, including targeted therapies and peptide receptor radionuclide therapy (PRRT), are enhancing patient outcomes and driving market growth. 

Market Dynamics

Global Neuroendocrine Tumors Treatment Market Drivers

Increasing Number of Clinical Trials:

The rising number of clinical trials for peptide-targeted radionuclide therapy development is driving the global neuroendocrine tumor treatment market. For example, Clovis Oncology, Inc. announced the initiation of the Phase 1/2 LuMIERE study of FAP-2286, a novel peptide-targeted radionuclide therapy and imaging agent. This study aims to evaluate the safety and efficacy of FAP-2286 in treating patients with FAP-positive tumors. Such clinical trials contribute to advancements in treatment options and drive market growth.

Growing Prevalence Of Neuroendocrine Cancer

The increasing incidence of neuroendocrine tumors globally is a major driver for the growth of the neuroendocrine tumor treatment market. As the prevalence of these tumors rises, there is a growing need for effective treatment options, leading to a surge in research, development, and investment in this field. The article "Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)" published in the Journal of Cancers in April 2022 highlights the increasing occurrence of neuroendocrine tumors over the past three to four decades. This results in increased advance treatment methods for neuroendocrine tumors, including somatostatin analogs, interferon alpha, radionuclide treatment, transarterial treatment, targeted therapy, immunotherapy, CAR-T-cell therapy, bispecific antibodies, vaccines, and cytotoxic chemotherapy for highly differentiated and low differentiated G1 and G2 GEP NETs. These innovations have significantly improved the growth of the neuroendocrine tumor treatment market in recent years.

Global Neuroendocrine Tumors Treatment Market Restraint

Therapeutic Challenges and Research Limitations

Pancreatic neuroendocrine tumors (PNETs) present significant therapeutic challenges due to their heterogeneity and varying growth rates, ranging from slow to aggressive. As per American Cancer Society, the prevalence of PNETs is increasing, with an estimated 4032 individuals diagnosed in 2020. Despite advancements, approved therapies often provide modest benefits or lack objective responses, highlighting the need for further research and novel treatment approaches. Current limitations include the lack of specific biomarkers for early diagnosis, limited preclinical models for research, and ineffectiveness of immunotherapy in this patient population. Emerging therapeutic targets offer promise for improving the management of PNETs, but more research is needed to address these challenges comprehensively.

Global Neuroendocrine Tumors Treatment Market Opportunities

Increasing Adoption of Growth Strategies

Market participants are increasingly adopting inorganic growth strategies, particularly collaboration, to enhance product sales, thereby stimulating the global neuroendocrine tumor treatment market's expansion. This trend is anticipated to fuel market growth significantly. In February 2024, RadioMedix, Inc. and Orano Med's AlphaMedixTM (212Pb-DOTAMTATE) has received FDA Breakthrough Therapy Designation for treating somatostatin receptor expressing gastroenteropancreatic neuroendocrine tumors. This Targeted Alpha Therapy, the first of its kind to receive such a designation, utilizes lead-212 (212Pb) to precisely target and kill cancer cells while minimizing damage to healthy tissue. AlphaMedixTM is currently in Phase 2 clinical development and shows promise in providing substantial benefits over existing PRRT options. The FDA's designation highlights the therapy's potential to redefine treatment for patients with GEP-NETs, accelerating its development and availability for those in need.

Regional Analysis

Based on region, the global neuroendocrine tumors treatment market is bifurcated into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.

North America Dominates the Global Market

North America is the most significant global neuroendocrine tumors treatment market shareholder and is expected to expand substantially during the forecast period due to growing need for advanced technology in neuroendocrine tumor treatment, coupled with increasing investments in the healthcare sector. This trend is expected to propel market growth in the region.

The United States neuroendocrine tumors treatment market is leading in terms of market share. According to the American Society of Clinical Oncology, more than 12,000 people in the U.S. are diagnosed with a neuroendocrine tumor each year, with approximately 175,000 people living with the diagnosis. This rise in cases fuels market growth. Further, the approval of new neuroendocrine tumor treatment drugs by the FDA, such as belzutifan (Welireg), is a significant driver for market growth. The rise in approvals of such drugs, along with supportive insurance policies like Medicare, Medicaid, and Tricare, contributes to the overall growth of the neuroendocrine tumors treatment market.

Canada is expected to become a key player in the global neuroendocrine tumors treatment market. Collaboration between healthcare providers, research institutions, and pharmaceutical companies in Canada enhances the development and adoption of new neuroendocrine tumor treatments. For instance, Princess Margaret cancer centre, a Toronto-based cancer research institute collaborates with pharmaceutical companies and other research institutions to conduct clinical trials and research on neuroendocrine tumors. These collaborations help in developing and testing new treatments for patients.

Europe region is expected to emerge in neuroendocrine tumors treatment market. Europe hosts numerous clinical trials for NETs, offering patients access to cutting-edge treatments and contributing to the expansion of knowledge about the disease. Further, several European governments provide funding and support for research and treatment of rare diseases, including NETs, which helps drive advancements in care.

U.K. neuroendocrine tumors treatment market is leading in terms of market share in the Europe neuroendocrine tumors treatment market due to presece of key manufacturers in this sector including AstraZeneca and GlaxoSmithKline. AstraZeneca showcased the potential of TAGRISSO  (osimertinib) and IMFINZI  (durvalumab) in early lung cancer settings. GlaxoSmithKline (GSK) received FDA accelerated approval for JEMPERLI (dostarlimab-gxly) for adult patients with mismatch repair-deficient (dMMR) recurrent or advanced solid tumors. GlaxoSmithKline (GSK) announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for a new combination regimen using Tykerb  (lapatinib) as a first-line, all-oral treatment for women with metastatic breast cancer. Such innovations are solidifing U.K.'s position in the market.

Germany is expected to emerge in neuroendocrine tumors treatment market. The country’s emergence in the neuroendocrine tumors (NETs) treatment market is supported by a study in the Journal of Cancer Research and Clinical Oncology, indicating a higher susceptibility to gastrointestinal NETs in Germany, with more large intestine NETs and fewer stomach NETs compared to other European countries. These insights are expected to drive tailored neuroendocrine tumors treatment approaches and improve outcomes, contributing to market growth in Germany.

Segmental Analysis

The global neuroendocrine tumors treatment market is segmented by treatment type and end-user.

Based on treatment type, the global neuroendocrine tumors treatment market is divided into surgical treatment, pharmacological treatment, and others.

The pharmacological treatment segment for neuroendocrine tumors treatment market is dominant. The segment is further subdivided into somatostatin analogues, targeted cancer drugs, and chemotherapy. Among these somatostatin analogues are dominant in treatment of neuroendocrine tumor. According to a study published in the Journal of Oncology, somatostatin analogs (SSAs) are one of the most preferred treatment methods for neuroendocrine tumors. SSAs are considered safe for use, which contributes to their high adoption rate. They offer a safe treatment procedure for patients, as indicated by a study published in the Journal of Patient-Reported Outcomes, where patients reported high satisfaction with long-acting injectable SSA therapy.

Many somatostatin analogues are currently under clinical trial phase and awaiting approval, indicating a growing interest and investment in this treatment modality. For example, Amyrt Pharma plc reported successful bioavailability study results for Mycapssa (octreotide capsules) in the treatment of carcinoid symptoms associated with Neuroendocrine Tumors (NET). This demonstrates the increasing research and development efforts in SSA therapy for neuroendocrine tumors.

Based on end-user, the global neuroendocrine tumors treatment market is divided into hospitals, clinics, and others.

The hospital segment dominates the global neuroendocrine tumors treatment market Hospitals are often equipped with specialized oncology departments staffed by experienced healthcare professionals who can accurately diagnose and effectively treat neuroendocrine tumors such as a multidisciplinary team approach, involving oncologists, surgeons, radiologists, and pathologists, which is critical for providing comprehensive care to patients with neuroendocrine tumors.  Additionally, hospitals typically have access to advanced treatment facilities, including surgical suites, imaging technologies, and radiation therapy equipment, which are essential for managing these complex tumors.

Hospitals are also often involved in clinical research and trials for new treatments and therapies for neuroendocrine tumors. This involvement in research not only benefits patients by providing access to cutting-edge treatments but also contributes to the advancement of medical knowledge and the development of new treatment options.

Overall, the hospital segment's dominance in the neuroendocrine tumors treatment market can be attributed to its ability to provide comprehensive care, access to advanced treatment facilities, multidisciplinary expertise, and involvement in research and clinical trials.

Recent Developments

• April 2024- Novartis revealed that its radioligand therapy, Lutathera has received approval from the U.S. Food and Drug Administration (FDA) for the treatment of pediatric patients aged 12 years and older with somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This approval marks a significant milestone as Lutathera is the first therapy to be specifically reviewed and approved for use in pediatric patients with GEP-NETs.
• November 2023- Boehringer Ingelheim announced the initiation of a Phase I dose escalation trial for BI 764532, a DLL3/CD3 IgG-like T cell engager, in combination with ezabenlimab, an anti-PD-1 antibody. The trial is being conducted in patients with small cell lung cancer (SCLC) and other neuroendocrine cancers.

Analyst’s Perspective

According to our research analysts, the outlook for the neuroendocrine tumor treatment market is promising, driven by several factors. Firstly, advancements in therapeutic options, such as radioligand therapy and immunotherapy, are improving patient outcomes and quality of life. Secondly, the increasing incidence of neuroendocrine tumors is creating a larger patient pool, driving market growth. Thirdly, regulatory bodies are supporting innovation in this space, expediting approvals for novel treatments. Additionally, the emphasis on personalized medicine is leading to tailored treatments that are more effective and have fewer side effects. Overall, with ongoing research, development of innovative therapies, and a growing market, the neuroendocrine tumor treatment industry is poised for significant growth and improvement in patient care.